资讯

Reversible posterior leukoencephalopathy syndrome (RPL) is characterized by white matter edema predominantly in the posterior parietal, temporal and occipital regions of the brain with ...
We describe progressive multifocal leukoencephalopathy (PML) caused by infection with human polyomavirus JC virus in a patient with multiple sclerosis who was treated with natalizumab. The first PM ...
Progressive Multifocal Leukoencephalopathy After Carboplatin and Paclitaxel Chemotherapy for Ovarian Carcinoma. JOP 15 , 554-555 (2019). DOI: 10.1200/JOP.19.00196 ...
Progressive multifocal leukoencephalopathy (PML) was reported to have developed in three patients treated with natalizumab. We conducted an evaluation to determine whether PML had developed in any ...
Summary This latest Pharmaceutical and Healthcare disease pipeline guide Progressive Multifocal Leukoencephalopathy - Drugs In Development, 2022, provides an overview of the Progressive Multifocal ...
Reversible posterior leukoencephalopathy syndrome is characterized clinically by headache, abnormalities of mental status and visual perception, and seizures. Despite its diverse causes, common ...
Methotrexate (MTX) can cause significant clinical neurotoxicity and asymptomatic leukoencephalopathy. We sought to identify clinical, pharmacokinetic, and genetic risk factors for these MTX-related ...
Repeat PCR testing for JC polyomavirus was positive; we diagnosed progressive multifocal leukoencephalopathy with immune reconstitution inflammatory syndrome. The weakness progressed to dense ...
Progressive multifocal leukoencephalopathy (PML) is a rare and often lethal brain disorder caused by the common, often benign polyomavirus 2, which is also News News CME CME ...
Monday, June 2, 2025. News & Perspective Drugs & Diseases CME & Education Video Decision Point close ...
Global Progressive Multifocal Leukoencephalopathy Treatment Market The global progressive multifocal leukoencephalopathy (PML) treatment market is projected to experience stable growth over the next ...